A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Inclusion Criteria Cohort B1: - Complete resection of the primary NSCLC with negative margins - Confirmed stage II to select stage IIIB (T3N2) NSCLC of non-squamous (adenocarcinoma) histology - Eastern cooperative oncology group (ECOG) performance status of 0 or 1 Inclusion Criteria Cohort B2: - Evaluation by the operating attending surgeon and involved medical oncologist prior to study enrollment to verify study eligibility for complete surgical resection with curative intent - Pathologically and/or histologically confirmed Stage II-IIIA and IIIB (T3N2 only) NSCLC of non-squamous (adenocarcinoma) histology Inclusion Criteria Cohorts B1 and B2: - Documented ALK fusion Exclusion Criteria Cohort B1: - NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation - Prior exposure to any systemic anti-cancer therapy Exclusion Criteria Cohort B2: - NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation - Known sensitivity to any component of alectinib, pemetrexed, cisplatin, or carboplatin - Prior exposure to any systemic anti-cancer therapy Exclusion Criteria Cohorts B1 and B2: - Pregnancy or breastfeeding, or intention of becoming pregnant during the study